Mental health concerns
Drug research and approvals for mental health concerns: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 6 studies of mental health concerns are recruiting on ClinicalTrials.gov, and Health Canada has authorized 7 drug trials for it since 2013.
- Recruiting worldwide: 6
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 6 recruiting on ClinicalTrials.gov ↗- Evaluating WhatsOK Helpline for Youth With Concerns About Sexual Thoughts and BehaviorsNCT07525778 · Not applicable · Center for Violence Prevention Research Inc · starts Apr 6, 2026
- Behavioral Health Collaborative Care Model in Post-ICU Clinic Family PilotNCT07390786 · Not applicable · Medical University of South Carolina · starts Jan 30, 2026
- Behavioral Health Collaborative Care Model in an ICU Recovery ClinicNCT07372586 · Not applicable · Medical University of South Carolina · starts Jan 30, 2026
- Enhancing Engagement by Integrating Goals and Concerns That Matter to PatientsNCT06898593 · Not applicable · Dartmouth-Hitchcock Medical Center · starts Apr 2, 2025
- Project Gnosis: the Neurophysical and Psychosocial Health Outcomes of Tai Chi for Older Adults with Cognitive Concerns…NCT06828926 · Not applicable · Ohio University · starts Feb 12, 2025
- Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical ADNCT05881239 · Not reported · Massachusetts General Hospital · starts May 9, 2023
Trials Authorized in Canada
Newest first; search them all in Canada trials| Jul 31, 2025 | Psilocybin microdose for psychchological and existential distress in palliative care (psyched-pal): a multi-site phase 3 double-blind, placebo-controlled,…PSILOCYBIN | BRUYÈRE HEALTH RESEARCH INSTITUTE | Ongoing |
| Jan 14, 2025 | Evaluating the effect of psilocybin-assisted group therapy on indicators of wellness in well and unwell individualsPSILOCYBIN (PEX010) | 16506607 CANADA INC | Pending |
| Jul 26, 2024 | Examining the impact 3,4-methylenedioxymethamphetamine assisted group therapy on measures of wellness: a pilot study isa 4-7METHYLENEDIOXYMETHAMPHETAMINE (MDMA) | GAURAV GUPTA | Pending |
| Feb 21, 2024 | Gathering group's study to examine the impact of psilocybin (4-phosphoryloxy-n,n-dimethyltryptamine) in assisted group therapy on measures of wellness.PSILOCYBIN | GATHERING RESILIENCE GROUPS INCORPORATED | Pending |
| Jan 17, 2024 | Conscious mind's study to examine the impact of psilocybin (4-phosphoryloxy-n,n-dimethyltryptamine) in assisted group therapy on measures of wellness.PSILOCYBIN | CONSCIOUS MIND CLINIC | Pending |
| Nov 23, 2023 | A phase II study assessing the efficacy of mdma when administered to frontline healthcare workers with mental health concernsMETHYLENEDIOXYMETHAMPHETAMINE (MDMA) | ATMA JOURNEY CENTRES | Pending |
| Jan 27, 2023 | A master protocol to examine the impact of psilocybin (4-phosphoryloxy-n,ndimethyltryptamine) in assisted group therapy on measures of wellnessPSILOCYBIN | GAURAV GUPTA | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA